Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Cody Hanson

Dermatology Saint Joseph, MO Doctor of Osteopathy

NPI 1306230784 CMS profile 2784952

5204 N Belt Hwy, Saint Joseph, MO 64506

Open in the dashboard

General payments

$1,442

52 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cody Hanson of Saint Joseph, MO is reported in the CMS Open Payments database as having received $1,442 across 52 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 40th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $253 12
2024 General $26 1
2023 General $15 1
2022 General $113 5
2021 General $163 9
2020 General $95 6
2019 General $777 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cody Hanson
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Cody Hanson were reported at $253. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Cody Hanson Dermatology median Middle half National median
2019 $777 $454 $129–$1,240 $163
2020 $95 $235 $81–$756 $114
2021 $163 $377 $108–$1,108 $132
2022 $113 $514 $143–$1,391 $149
2023 $15 $607 $159–$1,674 $160
2024 $26 $751 $204–$1,903 $164
2025 $253 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $557 13 payments
  2. Celgene Corporation $147 3 payments
  3. Janssen Biotech, Inc. $140 7 payments
  4. Amgen Inc. $100 5 payments
  5. Allergan Inc. $97 1 payment
  6. LEO Pharma Inc. $68 4 payments
  7. Lilly USA, LLC $49 3 payments
  8. Endo Pharmaceuticals Inc. $45 3 payments
  9. Regeneron Healthcare Solutions, Inc. $43 2 payments
  10. Genzyme Corporation $31 1 payment
  11. Other $165 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,442 52 payments
Products named General payments · program years 2019–2025
  1. HUMIRA $469 9 payments
  2. Otezla Dermatology $126 1 payment
  3. TREMFYA $101 5 payments
  4. BOTOX COSMETIC $97 1 payment
  5. Otezla Inflammation $77 4 payments
  6. ENSTILAR $68 4 payments
  7. DUPIXENT $62 2 payments
  8. SKYRIZI $55 3 payments
  9. TALTZ $49 3 payments
  10. XIAFLEX $45 3 payments
  11. Other $660 35 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

637

Median for Dermatology: 534

Drug cost

$980,937

Median for Dermatology: $67,151

Branded share of claims

23.7%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 15 $346,098
Humira(Cf) Pen Adalimumab Brand 19 $273,358
Dupixent Pen Dupilumab Brand 46 $187,476
Otezla Apremilast Brand 30 $159,972
Ketoconazole Generic 136 $2,690
Fluorouracil Generic 34 $2,300
Doxycycline Monohydrate Generic 24 $2,067
Clobetasol Propionate Generic 41 $1,446
Doxycycline Hyclate Generic 48 $1,045
Clindamycin Phosphate Generic 23 $712

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$109,509

Medicare's payments for the services billed

Medicare patients

830

Average age 74

Services billed

3,613

405 women, 425 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 41%
Ischemic heart disease 30%
Diabetes 28%
COPD 18%
Atrial fibrillation 16%
Chronic kidney disease 16%
Cancer 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

52 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record